Induced Pluripotent Stem Cell-Derived Hepatocytes From Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Exhibit Early Mitochondrial Dysfunction.

Dounia Le Guillou, Kevin Siao, Chris L Her, Caroline C Duwaerts, Jacquelyn J Maher

Abstract read

In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

Update of
iPSC-Derived Hepatocytes from Patients with MASLD Exhibit Early Mitochondrial Dysfunction.2025

5 · Who and what money

Authors and funding

5 authors.

Dounia Le GuillouDepartment of Medicine, University of California San Francisco, San Francisco, California; The Liver Center, University of California San Francisco, San Francisco, California. Electronic address: dounia.leguillou@ucsf.edu.

Kevin SiaoDepartment of Medicine, University of California San Francisco, San Francisco, California; The Liver Center, University of California San Francisco, San Francisco, California.

Chris L HerDepartment of Medicine, University of California San Francisco, San Francisco, California; The Liver Center, University of California San Francisco, San Francisco, California.

Caroline C DuwaertsDepartment of Medicine, University of California San Francisco, San Francisco, California; The Liver Center, University of California San Francisco, San Francisco, California.

Jacquelyn J MaherDepartment of Medicine, University of California San Francisco, San Francisco, California; The Liver Center, University of California San Francisco, San Francisco, California. Electronic address: jacquelyn.maher@ucsf.edu.

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026

$30.7M

Establishing patient-derived iPSCs as a platform for discovery research in NAFLDRC2DK136052 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JACQUELYN J. MAHER, Aras Nikodemas Mattis · 2023 to 2026

$6.4M

Using disease-specific iPS cells to investigate fatty liver disease in a diverse human cohortR21DK118380 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MAHER, JACQUELYN J. · 2018 to 2019

$441k

NIDDK NIH HHS P30 DK026743NIDDK NIH HHS R21 DK118380NIDDK NIH HHS RC2 DK136052

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42595208

DOI10.1016/j.jcmgh.2026.101853

PMCPMC13677320

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.